- Home
- SON vs MRUS Comparison
SON vs MRUS Comparison
Compare SON & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SON
- MRUS
- Stock Information
- Founded
- SON 1899
- MRUS 2003
- Country
- SON United States
- MRUS Netherlands
- Employees
- SON N/A
- MRUS N/A
- Industry
- SON Containers/Packaging
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- SON Consumer Discretionary
- MRUS Health Care
- Exchange
- SON Nasdaq
- MRUS Nasdaq
- Market Cap
- SON 4.3B
- MRUS 4.1B
- IPO Year
- SON N/A
- MRUS 2016
- Fundamental
- Price
- SON $48.17
- MRUS $66.27
- Analyst Decision
- SON Strong Buy
- MRUS Strong Buy
- Analyst Count
- SON 8
- MRUS 13
- Target Price
- SON $57.00
- MRUS $88.54
- AVG Volume (30 Days)
- SON 964.9K
- MRUS 641.0K
- Earning Date
- SON 07-23-2025
- MRUS 08-04-2025
- Dividend Yield
- SON 4.28%
- MRUS N/A
- EPS Growth
- SON 50.35
- MRUS N/A
- EPS
- SON 5.60
- MRUS N/A
- Revenue
- SON $6,337,597,000.00
- MRUS $54,732,000.00
- Revenue This Year
- SON $45.40
- MRUS $68.08
- Revenue Next Year
- SON $0.70
- MRUS $0.09
- P/E Ratio
- SON $8.68
- MRUS N/A
- Revenue Growth
- SON 28.33
- MRUS 42.77
- 52 Week Low
- SON $39.46
- MRUS $33.19
- 52 Week High
- SON $56.77
- MRUS $66.43
- Technical
- Relative Strength Index (RSI)
- SON 65.15
- MRUS 72.52
- Support Level
- SON $47.35
- MRUS $61.51
- Resistance Level
- SON $50.09
- MRUS $66.43
- Average True Range (ATR)
- SON 1.04
- MRUS 2.22
- MACD
- SON 0.27
- MRUS 0.90
- Stochastic Oscillator
- SON 66.13
- MRUS 89.90
About SON Sonoco Products Company
Over its 100-year-plus history, Sonoco Products has steadily assembled a diverse portfolio of industrial and consumer packaging product offerings such as flexible and rigid plastics, reels and spools, pallets, and composite cans. The company serves a variety of consumer and industrial end markets throughout North America. Sonoco has raised its dividend each year for more than 40 years.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.